Sanofi and Regeneron File Notice of Appeal and Motion to Stay (Suspend) Injunction with Federal Circuit Court of Appeals in Patent Case Regarding Praluent® (alirocumab) Injection

You are now leaving Investor.Regeneron.com. The site you are about to visit is maintained by a third party who is solely responsible for its content. We encourage you to read the privacy policy of every website you visit.

Continue

Release Details

Sanofi and Regeneron File Notice of Appeal and Motion to Stay (Suspend) Injunction with Federal Circuit Court of Appeals in Patent Case Regarding Praluent® (alirocumab) Injection